These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32436221)

  • 1. Nanomedicine: a new paradigm to overcome drug incompatibilities.
    Abdelkader A; Fathi HA; Hamad MA; Elsabahy M
    J Pharm Pharmacol; 2020 Oct; 72(10):1289-1305. PubMed ID: 32436221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Incompatibilities in intravenous therapy: What can be done to prevent them?].
    Secoli SR; Pérez-Esquirol E; de Las Heras-Matellán MJ; Vendrell-Bosh L; Ballarín-Alins E
    Enferm Clin; 2009; 19(6):349-53. PubMed ID: 19736025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units.
    Maison O; Tardy C; Cabelguenne D; Parat S; Ducastelle S; Piriou V; Lepape A; Lalande L
    Eur J Clin Pharmacol; 2019 Feb; 75(2):179-187. PubMed ID: 30543036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro toxicity assessment of oral nanocarriers.
    Ciappellano SG; Tedesco E; Venturini M; Benetti F
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):381-401. PubMed ID: 27544694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Nanotechnology for Cancer Therapy.
    Kumar V; Palazzolo S; Bayda S; Corona G; Toffoli G; Rizzolio F
    Theranostics; 2016; 6(5):710-25. PubMed ID: 27022418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of intravenous drug incompatibilities in intensive care units.
    Machotka O; Manak J; Kubena A; Vlcek J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):652-6. PubMed ID: 25482735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia.
    Valero L; Alhareth K; Gil S; Lecarpentier E; Tsatsaris V; Mignet N; Fournier T; Andrieux K
    Drug Discov Today; 2018 May; 23(5):1099-1107. PubMed ID: 29391261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities.
    Bertsche T; Veith C; Stahl A; Hoppe-Tichy T; Meyer FJ; Katus HA; Haefeli WE
    Pharm World Sci; 2010 Oct; 32(5):663-9. PubMed ID: 20694515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocarriers as Administration Systems of Natural Products.
    Solís-Cruz GY; Pérez-López LA; Alvarez-Roman R; Rivas-Galindo VM; Silva-Mares DA; Ibarra-Rivera TR
    Curr Top Med Chem; 2021; 21(26):2365-2373. PubMed ID: 34525921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomedical Applications of Multifunctional Polymeric Nanocarriers: A Review of Current Literature.
    Karabasz A; Bzowska M; Szczepanowicz K
    Int J Nanomedicine; 2020; 15():8673-8696. PubMed ID: 33192061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of intravenous drug incompatibilities in an intensive care unit.
    Bertsche T; Mayer Y; Stahl R; Hoppe-Tichy T; Encke J; Haefeli WE
    Am J Health Syst Pharm; 2008 Oct; 65(19):1834-40. PubMed ID: 18796425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.
    Zhang RX; Wong HL; Xue HY; Eoh JY; Wu XY
    J Control Release; 2016 Oct; 240():489-503. PubMed ID: 27287891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhalative pharmacotherapy in the future--nanocarriers for pulmonary drug delivery].
    Gessler T
    Pneumologie; 2009 Dec; 63 Suppl 2():S113-6. PubMed ID: 20013540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macromolecule nanotherapeutics: approaches and challenges.
    Tyagi P; Santos JL
    Drug Discov Today; 2018 May; 23(5):1053-1061. PubMed ID: 29326081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective loading of incompatible drugs into nanosized vesicles: a strategy to allow concurrent administration of furosemide and midazolam in simulated clinical settings.
    Fathi HA; Yousry C; Elsabahy M; El-Badry M; El Gazayerly ON
    Int J Pharm; 2023 Apr; 636():122852. PubMed ID: 36934884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why Anticancer Nanomedicine Needs Sugars?
    Bouffard E; El Cheikh K; Gallud A; Da Silva A; Maynadier M; Basile I; Gary-Bobo M; Morere A; Garcia M
    Curr Med Chem; 2015; 22(26):3014-24. PubMed ID: 26242256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities.
    Mohamed HB; El-Shanawany SM; Hamad MA; Elsabahy M
    Sci Rep; 2017 Jul; 7(1):6340. PubMed ID: 28740102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
    Frazier N; Ghandehari H
    Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationally designed DNA-based nanocarriers.
    Jiang Q; Zhao S; Liu J; Song L; Wang ZG; Ding B
    Adv Drug Deliv Rev; 2019 Jul; 147():2-21. PubMed ID: 30769047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug incompatibilities in the adult intensive care unit of a university hospital.
    Marsilio NR; Silva Dd; Bueno D
    Rev Bras Ter Intensiva; 2016 Jun; 28(2):147-53. PubMed ID: 27410410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.